US20080177085A1 - Process for the Synthesis of a CPLA2 Inhibitor - Google Patents

Process for the Synthesis of a CPLA2 Inhibitor Download PDF

Info

Publication number
US20080177085A1
US20080177085A1 US12/041,988 US4198808A US2008177085A1 US 20080177085 A1 US20080177085 A1 US 20080177085A1 US 4198808 A US4198808 A US 4198808A US 2008177085 A1 US2008177085 A1 US 2008177085A1
Authority
US
United States
Prior art keywords
phenyl
alkyl
compound
chloro
benzhydryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/041,988
Inventor
Christoph M. Dehnhardt
Sreenivasulu Megati
Ronald S. Michalak
Panolil Raveendranath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US12/041,988 priority Critical patent/US20080177085A1/en
Publication of US20080177085A1 publication Critical patent/US20080177085A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • This invention relates to a new process for the synthesis of a key intermediate for making certain compounds that inhibit cytosolic phospholipase A 2 (cPLA 2 ), and related compounds.
  • a process disclosed in U.S. patent application Ser. No. 10/302636 for making 4-(3-[1-benzhydryl-5-chloro-2-(2- ⁇ [3,4-dichlorobenzyl)sulfonyl]amino ⁇ ethyl)-1H-indol-3-yl]propyl ⁇ benzoic acid may be summarized as follows: methyl-4-iodobenzoate is reacted with allyl alcohol to provide 4-(3-Oxo-propyl)-benzoic acid methyl ester, which is then reacted with 5-chloro-2-methylindole to yield 4-[3-(5-chloro-2-methylindol-3-yl)propyl]benzoic acid methyl ester; this product is reacted with benzhydryl bromide to produce 4-[3-(1-benzhydryl-5-chloro-2-methylindol-3-yl)propyl]benzoic acid methyl ester,
  • the invention comprises a process for making a substituted indole compound, said process comprising the steps of:
  • Ph represents phenyl
  • X represents a moiety selected from the group consisting of H, F, Cl, Br, C 1 -C 10 -alkyl, C 3 -C 10 -cycloalkyl, and C 6 -C 10 -aryl, the alkyl moiety being optionally substituted with one or more atoms selected from F, Cl and Br, and the cycloalkyl and aryl moieties being optionally substituted with from one to three substituents selected from F, Cl, Br and C 1 -C 6 -alkyl; and then, b) heating said intermediate compound in the solvent in the presence of the catalyst to form the substituted indole compound
  • X is F, Cl, or Br, most preferably Cl.
  • the process of this invention may comprise further one or more reaction shown below steps:
  • R represents C 1 -C 6 -alkyl, phenyl, —CH 2 O-phenyl, —CH 2 O—(C 1 -C 6 -alkyl), —CH 2 -phenyl, —CH 2 CH 2 -phenyl, or —CH 2 -phenyl-COOZ; and Z represents H or C 1 -C 6 -alkyl; d) hydrolyzing said tetra-substituted indole compound under alkali conditions to form the primary amine
  • Y represents (CH 2 ) 2 —Y 1 , n represents an integer form 0 to 4; Y 1 represents a chemical bond, S, O, S(O), S(O 2 , C ⁇ C, NH, N(C 1 -C 6 alkyl), NH—C(O), or NH(C 1 -C 6 alkyl)—C(O); and Ar represents a moiety selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 fluorinated alkyl, C 3 -C 6 cycloalkyl, tetrahydropyranyl, camphoryl, adamantyl, CN, —N(C 1 -C 6 alkyl) 2 , phenyl, pyridinyl, pyrimidinyl, furyl, thienyl, napthyl, morpholinyl, triazolyl, pyrazolyl, piperidinyl, pyrrolidinyl, imidazo
  • the substituted phenyl reactant may be made by the process:
  • This invention further comprises novel intermediate compounds and other novel compounds created in the process of this invention, especially benzhydryl-(4-chloro-2-iodo-phenyl)-amine, 2- ⁇ 4-[2-(benzhydryl-amino)-5-chloro-phenyl]-but-3-ynyl ⁇ -isoindole-1,3-dione, 2-[2-(1-benzhydryl-5-chloro-1H-indol-2-yl)-ethyl]-isoindole-1,3-dione, 4-(3- ⁇ 1-benzhydryl-5-chloro-2-[2-( 1,3-dioxo-1 ,3-dihydro-isoindol-2-yl)-ethyl]-1H-indol-3-yl ⁇ -propyl)-benzoic acid ethyl ester, and 4-(3,3-bis- ⁇ 1-benzhydryl-5-chloro-2-[2-
  • Ph represents phenyl
  • Y represents (CH 2 ) n —Y 1 ; n represents an integer form 0 to 4; Y 1 represents a chemical bond, S, O, S(O), S(O 2 , C ⁇ C, NH, N(C 1 -C 6 alkyl), NH—C(O), or NH(C 1 -C 6 alkyl)—C(O);
  • Ar represents a moiety selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 fluorinated alkyl, C 3 -C 6 cycloalkyl, tetrahydropyranyl, camphoryl, adamantyl, CN, —N(C 1 -C 6 alkyl) 2 , phenyl, pyridinyl, pyrimidinyl, furyl, thienyl, napthyl, morpholinyl, triazolyl, pyrazolyl, piperidinyl, pyr
  • R represents C 1 -C 6 -alkyl, phenyl, —CH 2 O-phenyl, —CH 2 O—(C 1 -C 6 -alkyl), —CH 2 -phenyl, —CH 2 CH 2 -phenyl, or —CH 2 -phenyl-COOZ;
  • Z represents H or C 1 -C 6 -alkyl;
  • X represents a moiety selected from the group consisting of H, F, Cl, Br, C 1 -C 10 -alkyl, C 3 -C 10 -cycloalkyl, and C 6 -C 10 -aryl, the alkyl moiety being optionally substituted with one or more atoms selected from F, Cl and Br, and the cycloalkyl and aryl moieties being optionally substituted with from one to three substituents selected from F, Cl, Br and C 1 -C 6 -alkyl.
  • the reaction of the 4-substituted aniline 2 with diphenylmethanol produces a surprisingly high yield of the resulting intermediate compound 9, typically about 80-90% yield.
  • the cyclization of the butynylaniline intermediate 11 to form an indole 12 also proceeds with surprisingly high yield, typically about 85-95% yield.
  • the process of the present invention does not require the use of chromatography to isolate or purify intermediate compounds.
  • the process of this invention represents a cost-effective, efficient, high-yielding route to cPLA 2 inhibitors such as 4-(3- ⁇ 1-Benzhydryl-5-chloro-2-[2-(3,4-dichloro-phenylmethanesulfonylamino)-ethyl]-1H-indol-3-yl ⁇ -propyl)-benzoic acid, and similar compounds.
  • the product 11 can be precipitated from the reaction mixture after addition of water in high yield and purity.
  • the benzhydrylated indole 12 is reductive alkylated with an aldehyde 5, chloroacetic acid and triethyl-silane to provide a 3-substituted indole 13 after crystallization from ethanol/acetonitrile.
  • Hydrolysis under Claisen alkali condition produces the penultimate compound 14.
  • Chloroacetic acid is an especially preferred acid in the process of this invention. Chloroacetic acid provides enough acidity for product formation without producing undesirable amounts of impurities.
  • One impurity that can be produced in the reductive alkylation is a bis(substituted-indole) compound of the formula
  • Phth means phthaloyl.
  • This compound can also lead to the final product, since under acidic conditions it can be cleaved to form the desired substituted indole compound.
  • An example of such a compound is 4-(3,3-bis- ⁇ 1-benzhydryl-5-chloro-2-[2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-1H-indol-3-yl ⁇ -propyl)-benzoic acid ethyl ester 15 (X ⁇ Cl; R ⁇ p-benzoic acid ethyl ester), which can be converted to the compound 13 under acidic conditions.
  • non-protic polar solvents may be used in the process of this invention.
  • the most preferred solvent for the reaction steps in which compounds 9 and 10 to produce compounds 11 and 12 is N,N-dimethylformamide (DMF).
  • the chlorinated hydrocarbons, such as methylene chloride and ethylene chloride, are particularly preferred solvents in the reductive alkylation of compound 12 to form compound 13; these solvents have been found to promote complete consumption of the starting material.
  • Milder reducing agents such as triethylsilane (TESH) and triphenylsilane, are preferred because they tend to provide higher yields and lower amounts of impurities.
  • TSH triethylsilane
  • triphenylsilane are preferred because they tend to provide higher yields and lower amounts of impurities.

Abstract

A process for making a substituted indole compound, including the steps of: reacting the compounds
Figure US20080177085A1-20080724-C00001
in a non-protic polar solvent in the presence of a catalyst to form the intermediate compound
Figure US20080177085A1-20080724-C00002
wherein Ph and X are as defined herein; and then, heating this intermediate compound in the solvent in the presence of the catalyst to form the substituted indole compound
Figure US20080177085A1-20080724-C00003
The invention also includes compounds formed by this process.

Description

  • This application claims priority from copending provisional application Ser. No. 60/507,235, filed on Sep. 30, 2003.
  • FIELD OF THE INVENTION
  • This invention relates to a new process for the synthesis of a key intermediate for making certain compounds that inhibit cytosolic phospholipase A2 (cPLA2), and related compounds.
  • BACKGROUND OF THE INVENTION
  • Compounds which inhibit cytosolic phospholipase A2 have been disclosed in U.S. patent application Ser. No. 10/302,636 filed Nov. 22, 2002, the disclosure of which is incorporated by reference herein. These compounds are useful for a variety of pharmaceutical purposes, including the relief of pain and inflammation. In order to bring a pharmaceutical compound to market, it is necessary to have an economically feasible process for making the compound. Often, a process that works in the laboratory is not practical from a commercial standpoint. It would be desirable to have a relatively inexpensive and efficient method for making at least some of the aforesaid compounds.
  • A process disclosed in U.S. patent application Ser. No. 10/302636 for making 4-(3-[1-benzhydryl-5-chloro-2-(2-{[3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1H-indol-3-yl]propyl}benzoic acid may be summarized as follows: methyl-4-iodobenzoate is reacted with allyl alcohol to provide 4-(3-Oxo-propyl)-benzoic acid methyl ester, which is then reacted with 5-chloro-2-methylindole to yield 4-[3-(5-chloro-2-methylindol-3-yl)propyl]benzoic acid methyl ester; this product is reacted with benzhydryl bromide to produce 4-[3-(1-benzhydryl-5-chloro-2-methylindol-3-yl)propyl]benzoic acid methyl ester, which is then reacted with benzoyl peroxide to produce the 2-formyl indole; the 2 formyl indole is then reacted with nitromethane followed by Zn(Hg)/HCl to form the 2-(2-aminoethyl) indole; this amine is then reacted with [(3,4-dichlorophenyl)-methyl]sulfonyl chloride to produce 4-{3-[1-benzhydryl-5-chloro-2-(2-{[3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1H-indol-3-y]propyl}benzoic acid methyl ester, which is then hydrolyzed to form 4-{3-[1-benzhydryl-5-chloro-2-(2-{[3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1H-indol-3-yl]propyl}benzoic acid. In this process, chromatography is used to separate some of the compounds made in the aforesaid reactions. It would be desirable to have a process for making the product that does not require the use of chromatography.
  • Appleton, et al., in Tetrahedron Lett. 1993, 34, 1529, teach reductive C-3 alkylation of 3-unsubstituted indoles to produce C-3 functionalized indoles, especially 3-(arylmethyl)indoles and 3-(heteroarylmethyl)indoles. In the reference reaction, the initial indole is reacted with an aldehyde or ketone using triethylsilane and trifluoroacetic acid.
  • A method for synthesizing N-but-3-ynylphthalimide is taught by Hoffmann, et al., J. Med. Chem., 18(3), 278-284 (1975). In this method, phthalic acid anhydride is reacted with 4-amino-1-butyne in glacial acetic acid to produce the target compound.
  • Ezquerra, et al., in J. Org. Chem. 1998, 61, 5804-5812, disclose methods for making substituted indoles starting from aromatic amines. For example, they disclose that a 2,4-substituted aniline may be reacted with bis(pyridine)iodonium(I) tetrafluoroborate to create a 2-iodo-4,6-substituted aniline in high yield. The iodoaniline may be reacted with HC≡CS(Me)3 followed by Cul in DMF to form a 5,7-substituted indole.
  • Xiao, et al., J. Org. Chem., 64, 9646-9652 (1999), have described a preparation for 2-iodoaniline in which a 4-substituted aniline is reacted with iodine in an aqueous sodium bicarbonate solution. The authors also describe using 2-iodoaniline in the synthesis of other compounds.
  • Pierce, et al., in J. Org. Chem. 1998, 63, 8536, disclose a method for making N-benzyl anilines.
  • Villemin and Goussu, in Hetereocycles 1989, 29, 1255, disclose a method and conditions for the cyclization of 2-acetyleno-anilines.
  • SUMMARY OF THE INVENTION
  • The invention comprises a process for making a substituted indole compound, said process comprising the steps of:
  • a) reacting the compounds
  • Figure US20080177085A1-20080724-C00004
  • in a non-protic polar solvent in the presence of a catalyst to form the intermediate compound
  • Figure US20080177085A1-20080724-C00005
  • wherein Ph represents phenyl; and
    X represents a moiety selected from the group consisting of H, F, Cl, Br, C1-C10-alkyl, C3-C10-cycloalkyl, and C6-C10-aryl, the alkyl moiety being optionally substituted with one or more atoms selected from F, Cl and Br, and the cycloalkyl and aryl moieties being optionally substituted with from one to three substituents selected from F, Cl, Br and C1-C6-alkyl; and then,
    b) heating said intermediate compound in the solvent in the presence of the catalyst to form the substituted indole compound
  • Figure US20080177085A1-20080724-C00006
  • Preferably, X is F, Cl, or Br, most preferably Cl.
  • The process of this invention may comprise further one or more reaction shown below steps:
  • c) reacting said substituted indole compound with the aldehyde R—CH2CH═O or with
  • Figure US20080177085A1-20080724-C00007
  • to form the tetra-substituted indole compound
  • Figure US20080177085A1-20080724-C00008
  • wherein
    R represents C1-C6-alkyl, phenyl, —CH2O-phenyl, —CH2O—(C1-C6-alkyl), —CH2-phenyl, —CH2CH2-phenyl, or —CH2-phenyl-COOZ; and
    Z represents H or C1-C6-alkyl;
    d) hydrolyzing said tetra-substituted indole compound under alkali conditions to form the primary amine
  • Figure US20080177085A1-20080724-C00009
  • d) reacting said primary amine with
  • Figure US20080177085A1-20080724-C00010
  • to form the compound
  • Figure US20080177085A1-20080724-C00011
  • wherein Y represents (CH2)2—Y1,
    n represents an integer form 0 to 4;
    Y1 represents a chemical bond, S, O, S(O), S(O2, C═C, NH, N(C1-C6alkyl), NH—C(O), or NH(C1-C6alkyl)—C(O); and
    Ar represents a moiety selected from the group consisting of C1-C6 alkyl, C1-C6 fluorinated alkyl, C3-C6 cycloalkyl, tetrahydropyranyl, camphoryl, adamantyl, CN, —N(C1-C6 alkyl)2, phenyl, pyridinyl, pyrimidinyl, furyl, thienyl, napthyl, morpholinyl, triazolyl, pyrazolyl, piperidinyl, pyrrolidinyl, imidazolyl, piperizinyl, thiazolidinyl, thiomorpholinyl, tetrazole, indole, benzoxazole, benzofuran, imidazolidine-2-thione, 7,7,dimethyl-bicyclo[2.2.1]heptan-2-one and pyrrolyl groups, each optionally substituted by from 1 to 3 substituents independently selected from the group consisting of halogen, —CN, —CHO, —CF3, OCF3, —OH, —C1-C6 alkyl, C1-C6 alkoxy, —NH2, —N(C1-C6)2, —NH(C1-C6), —N—C(O)—(C1-C6), —NO2, —SO2(C1-C3 alkyl), —SO2NH2, —SO2NH(C1-C3 alkyl), —SO2N(C1-C3 alkyl)2, —COOH, —CH2—COOH, —CH2—N(C1-C6 alkyl), —CH2—N(C1-C6 alkyl)2, —CH2—NH2, pyridine,
  • Figure US20080177085A1-20080724-C00012
  • In the process of this invention, the substituted phenyl reactant may be made by the process:
  • Figure US20080177085A1-20080724-C00013
  • This invention further comprises novel intermediate compounds and other novel compounds created in the process of this invention, especially benzhydryl-(4-chloro-2-iodo-phenyl)-amine, 2-{4-[2-(benzhydryl-amino)-5-chloro-phenyl]-but-3-ynyl}-isoindole-1,3-dione, 2-[2-(1-benzhydryl-5-chloro-1H-indol-2-yl)-ethyl]-isoindole-1,3-dione, 4-(3-{1-benzhydryl-5-chloro-2-[2-( 1,3-dioxo-1 ,3-dihydro-isoindol-2-yl)-ethyl]-1H-indol-3-yl}-propyl)-benzoic acid ethyl ester, and 4-(3,3-bis-{1-benzhydryl-5-chloro-2-[2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-1H-indol-3-yl}-propyl)-benzoic acid ethyl ester.
  • Many advantages and objects of the present invention will be apparent to those skilled in the art from the following detailed description and from the appended claims.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • A preferred embodiment of the present invention is illustrated below:
  • Figure US20080177085A1-20080724-C00014
  • wherein
    Ph represents phenyl;
    Y represents (CH2)n—Y1;
    n represents an integer form 0 to 4;
    Y1 represents a chemical bond, S, O, S(O), S(O2, C═C, NH, N(C1-C6alkyl), NH—C(O), or NH(C1-C6alkyl)—C(O);
    Ar represents a moiety selected from the group consisting of C1-C6 alkyl, C1-C6 fluorinated alkyl, C3-C6 cycloalkyl, tetrahydropyranyl, camphoryl, adamantyl, CN, —N(C1-C6 alkyl)2, phenyl, pyridinyl, pyrimidinyl, furyl, thienyl, napthyl, morpholinyl, triazolyl, pyrazolyl, piperidinyl, pyrrolidinyl, imidazolyl, piperizinyl, thiazolidinyl, thiomorpholinyl, tetrazole, indole, benzoxazole, benzofuran, imidazolidine-2-thione, 7,7,dimethyl-bicyclo[2.2.1]heptan-2-one and pyrrolyl groups, each optionally substituted by from 1 to 3 substituents independently selected from the group consisting of halogen, —CN, —CHO, —CF3, OCF3, —OH, —C1-C6 alkyl, C1-C6 alkoxy, —NH2, —N(C1-C6)2, —NH(C1-C6), —N—C(O)—(C1-C6), —NO2, —SO2(C1-C3 alkyl), —SO2NH2, —SO2NH(C1-C3 alkyl), —SO2N(C1-C3 alkyl)2, —COOH, —CH2—COOH, —CH2—N(C1-C6 alkyl), —CH2—N(C1-C6 alkyl)2, —CH2—NH2, pyridine,
  • Figure US20080177085A1-20080724-C00015
  • R represents C1-C6-alkyl, phenyl, —CH2O-phenyl, —CH2O—(C1-C6-alkyl), —CH2-phenyl, —CH2CH2-phenyl, or —CH2-phenyl-COOZ;
    Z represents H or C1-C6-alkyl; and
    X represents a moiety selected from the group consisting of H, F, Cl, Br, C1-C10-alkyl, C3-C10-cycloalkyl, and C6-C10-aryl, the alkyl moiety being optionally substituted with one or more atoms selected from F, Cl and Br, and the cycloalkyl and aryl moieties being optionally substituted with from one to three substituents selected from F, Cl, Br and C1-C6-alkyl.
  • A highly preferred embodiment of the present invention is shown below:
  • Figure US20080177085A1-20080724-C00016
  • In the process of this invention, the reaction of the 4-substituted aniline 2 with diphenylmethanol produces a surprisingly high yield of the resulting intermediate compound 9, typically about 80-90% yield. The cyclization of the butynylaniline intermediate 11 to form an indole 12 also proceeds with surprisingly high yield, typically about 85-95% yield.
  • Advantageously, the process of the present invention does not require the use of chromatography to isolate or purify intermediate compounds.
  • The process of this invention represents a cost-effective, efficient, high-yielding route to cPLA2 inhibitors such as 4-(3-{1-Benzhydryl-5-chloro-2-[2-(3,4-dichloro-phenylmethanesulfonylamino)-ethyl]-1H-indol-3-yl}-propyl)-benzoic acid, and similar compounds.
  • In one aspect of this invention, it has been discovered that in coupling the benzhydrylaniline 9 with phthalimdo-butyne 10, the well-known Sonogashira reaction, DMF is preferable to THF to avoid high amounts of a bis-acetylenic impurity. In this embodiment, the product 11 can be precipitated from the reaction mixture after addition of water in high yield and purity.
  • It is also preferred to perform the cyclization to the N-benzhydryl-4-chloro-N-phthalimido-ethyl-indole 12 in DMF at about 100° C. to 150° C., and more preferably at about 140° C., under Cul catalysis, according to the general condition for the cyclisation to 2-acetyleno-anilnes described first by Vilemins and coworkers (Hetereocycles 1989, 29, 1255). However, it has been found that this method is surprisingly efficient for the cyclization of the diphenylmethyl substituted precursors of the present invention.
  • Preferably, the benzhydrylated indole 12 is reductive alkylated with an aldehyde 5, chloroacetic acid and triethyl-silane to provide a 3-substituted indole 13 after crystallization from ethanol/acetonitrile. Hydrolysis under Claisen alkali condition produces the penultimate compound 14. Chloroacetic acid is an especially preferred acid in the process of this invention. Chloroacetic acid provides enough acidity for product formation without producing undesirable amounts of impurities. One impurity that can be produced in the reductive alkylation is a bis(substituted-indole) compound of the formula
  • Figure US20080177085A1-20080724-C00017
  • where Phth means phthaloyl. This compound can also lead to the final product, since under acidic conditions it can be cleaved to form the desired substituted indole compound. An example of such a compound is 4-(3,3-bis-{1-benzhydryl-5-chloro-2-[2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-1H-indol-3-yl}-propyl)-benzoic acid ethyl ester 15 (X═Cl; R═p-benzoic acid ethyl ester), which can be converted to the compound 13 under acidic conditions.
  • Those skilled in the art will appreciate that a number of non-protic polar solvents may be used in the process of this invention. The most preferred solvent for the reaction steps in which compounds 9 and 10 to produce compounds 11 and 12 is N,N-dimethylformamide (DMF). The chlorinated hydrocarbons, such as methylene chloride and ethylene chloride, are particularly preferred solvents in the reductive alkylation of compound 12 to form compound 13; these solvents have been found to promote complete consumption of the starting material.
  • In the practice of this invention, those skilled in the art will appreciate that many reducing agents may be used. Milder reducing agents, such as triethylsilane (TESH) and triphenylsilane, are preferred because they tend to provide higher yields and lower amounts of impurities.
  • Starting materials in the process of this invention, such as compounds 2, 5, 10, and the like, can be obtained by methods well known to those skilled in the art.
  • The following examples are presented to illustrate certain embodiments of the present invention, but should not be construed as limiting the scope of this invention.
  • EXAMPLE 1 Synthesis of Benzhydryl-(4-Chloro-2-Iodo-Phenyl)-Amine
  • To a nitrogen purged 2 L three necked flask equipped with addition funnel, overhead stirrer and reflux condenser was charged 150 g (0.591 mol) 4-Chloro-2-iodo-phenylamine, 3 g (0.018 mol, 0.03 eq) benzenesulfonic acid and 500 mL acetontrile. The mixture was warmed to 70 C and 120 g (0.652 mol, 1.1 eq) benzhydrol dissolved in 500 mL acetonitrile was added to the stirred warm solution over a period of 7.5 h. After another 4 h, LC analysis showed 95% product and 5% starting material remaining. The mixture was cooled to 25 C and 290 mL water was added dropwise over a period of 30-40 min. Stirring was continued over night at 23 C. The dark purple solid was collected by filtration, washed with 2× with MeCN/water 1/1 dried at 50 C in vacuo for 15 h to give 218.5 g (88%) product.
  • 1H NMR (300 MHz, DMSO-d6): δ=5.02 (d, j=5.9 Hz, 1H), 5.78 (d, j=5.9 Hz, 1H), 6.45 ( d, j=8.9 Hz, 1H), 7.16 (dd, j=8.9, 2.4 Hz, 1H), 7.24-7.42 (m, 10H), 7.71 (d, j=2.4 Hz, 1H) ppm.
  • EXAMPLE 2 Synthesis of 2-{4-[24Benzhydryl-Amino)-5-Chloro-Phenyl]-But-3-Ynyl}-Isoindole-1,3-Dione
  • 5 g( 1.93 mmol, 1 eq) benzhydryl-(4-chloro-2-iodo-phenyl)-amine made in Example 1 was combined with 5 mL DMF. 0.42 g (0.598 mmol, 0.05 eq) dichlorobis-(triphenylphosphine)-palladium, 0.24 g (1.26 mmol, 0.11 eq) copper iodide and 1.8 g (17.58 mmol, 1.5 eq) triethylamine were added. The mixture was stirred at 25C and 2.72 g (13.65 mmol, 1.14 eq) 2-but-3-ynyl-isoindole-1,3-dione was added in one portion. The mixture warmed to 40C and was cooled back to room temperature. It became semi-solid after 2 h; an LC showed that at this time the reaction was complete. The mixture was diluted with 10 mL DMF and then 5 mL water was added slowly. Stirring was continued until solids precipitated. The vessel was cooled to 0-5 C and stirred at this temperature for 30 min. The resulting solid was collected by filtration and washed with 10 mL DMF/water2:1 and 2×10 mL MeOH. The 8.78 g wet solid was dried at 40 C in vacuo for 14 h to obtain 5.55 g product (95%) with 95% purity.
  • 1H NMR (300 MHz, DMSO-d6): δ=2.87 (t, j=6.6 Hz, 2H), 3.82 (t, j=6.6 Hz, 2H), 5.46 (d, j=6.6 Hz, 1H), 5.74 (d, j=6.6 Hz, 1H), 6.45 (d, j=8.5 Hz, 1H), 7.06 (m, 2H), 7.24-7.37(m, 10H), 7.84-7.91 (m, 6H) ppm.
  • EXAMPLE 3 Synthesis of 2-[2-(1-Benzhydryl-5-Chloro-1H-Indol-2-Yl)-Ethyl]-Isoindole-1,3-Dione
  • To a solution of 2-{4-[2-(Benzhydryl-amino)-5-chloro-phenyl]-but-3-ynyl}-isoindole-1,3-dione made in Example 2 (13.1 g, 26.7 mmol) in dimethylformamide (65 ml) at ambient temperature was added copper iodide ( 1.02 g, 5.3 mmol). The reaction mixture suspension was heated at 120 C for 16 h. Then it was heated at 140 C for 4 h. The reaction mixture was filtered at 60 C. Water (200 ml) was added to the filtrate. The product was collected after filtration and washing with water (20 ml×4). Drying the product in vacuo at 60° C. provided an off-white solid product, 2-[2-(1-Benzhydryl-5-chloro-1H-indol-2-yl)-ethyl]-isoindole-1,3-dione (12.5 g, yield 95%).
  • HPLC (area%): 97.3%
  • 1H NMR (300 MHz, DMSO-d6): δ=3.11 (t, 2H, J=7.0 Hz), 3.90 (t, 2H, J=7.0 Hz), 6.36 (s, 1H), 6.53 (d, 1H, J=8.9 Hz), 6.80 (dd, 1H, J=8.9, 2.1 Hz), 7. 14 (m, 4H), 7.20 (s, 1H), 7.34 (m, 6H), 7.47 (d, 1H, J=2.1 Hz), 7.85 (m, 4H). EXAMPLE 4 Synthesis of 4-(3-{1-Benzhydryl-5-Chloro-2-[2-(1,3-Dioxo-1,3-Dihydro-Isoindol-2-Yl)-Ethyl]-1H-Indol-3-Yl}-Propyl)-Benzoic Acid Ethyl Ester
  • 4.91 g (10.0 mmol, 1 eq) 2-[2-(1-Benzhydryl-5-chloro-1H-indol-2-yl)-ethyl]-isoindole-1,3-dione made according to Example 3 was suspended in 50 mL CH2Cl2. 3.50 g (30.0 mmol, 3 eq) triethylsilane, 2.47 g (12 mmol, 1.2 eq) 4-(3-Oxo-propyl)-benzoic acid ethyl ester and chloro-acetic acid 7.56 g (80 mmol, 8 eq) were added in one portion. The mixture was heated to reflux for 92 h. LC showed less then 2% starting material at this end point. 15 mL sat. aq. NaHCO3 and 10 mL water was added to the reaction mixture, and stirring was continued over a period of 16 h. 10 mL MeOH was then added and the solid was collected by filtration. 9.4 g off-white solid was dried in the oven for 3 h at 60° C. to give 6.12 g 4-(3-1-Benzhydryl-5-chloro-2-[2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-1H-indol-3-yl}-propyl)-benzoic acid ethyl ester (90% yield) with 74% purity.
  • 3.55 g of crude material was further purified by recrystallization from 15 mL ethanol/acetonitrile (1:1) to give 1.9 g product (54% yield). The overall yield for this step was 48%.
    1H NMR (300 MHz, DMSO-d6): δ=1.31 (t, j=7.2 Hz, 3H), 1.78 (m,2H), 2.53 (t, j=7.6 Hz, 2H), 2.60 (t, j=7.6 Hz, 2H), 3.05 (t, j=6.9 Hz, 2H), 3.76 (t, j=6.9 Hz, 2H), 4.29 (q, j=7.2 Hz, 2H), 6.43 (d, j=8.9 Hz, 1H), 6.78 (dd, j=2.1, 8.9 Hz, 1H), 7.18-7.24 (m, 7H), 7.35-7.41 (m, 6H), 7.42 (d, j=2.1 Hz, 1H), 7.79-7.86 (m, 6H) ppm.
  • EXAMPLE 5 Synthesis of 4-(3,3-Bis-{1-Benzhydryl-5-Chloro-2-[2-(1,3-Dioxo-1,3-Dihydro-Isoindol-2-Yl)-Ethyl]-1H-Indol-3-Yl}-Propyl)-Benzoic Acid Ethyl Ester
  • Following the method of Example 4, the compound 4-(3,3-Bis-{1-benzhydryl-5-chloro-2-[2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-1H-indol-3-yl}-propyl)-benzoic acid ethyl ester is formed in minor amounts.
  • 1H NMR (300 MHz, DMSO-d6): δ=1.29 (t, j=7.1 Hz, 3H), 2.58 (s, 2H), 2.95 (m, 2H), 3.55-3.75 (m, 4H), 4.28 (q, j=7.1 Hz, 2H), 4.43 (m, 1H), 6.36 (d, j=9.0 Hz, 2H), 6.81 (dd, j=9.0 Hz, 1.9 Hz, 2H), 6.85 (d, j=6.85 Hz, 2H), 7.03-7.19 (m, 16H), 7.31-7.33 (m, 8H), 7.46 (d, j=1.9 Hz, 2H), 7.80-7.82 (m, 10H) ppm.
  • EXAMPLE 6 Synthesis of 4-{2-[2-(2-Amino-Ethyl)-1-Benzhydryl-5-Chloro-1H-Indol-3-Yl]-Propyl}-Benzoic Acid
  • 320 mg (0.47 mmol, 1 eq) 4-(3-{1-Benzhydryl-5-chloro-2-[2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-1H-indol-3-yl}-propyl)-benzoic acid ethyl ester made according to Example 4 was dissolved in 1 ml MeOH and 0.28 ml water, 606 mg (10.81 mmol, 20 eq) potassium hydroxide was added, and the mixture was heated to reflux for 15 h. LC showed a completed reaction at that time. The mixture was neutralized with 1 N HCl. The product formed a semi-solid which was collected after decanting the solvent. The compound was dried between two sheets of filter paper. 228 mg (93%) of solid was obtained. Co-injection with a known sample of the product, and 1H-NMR confirmed the structure of 4-{2-[2-(2-Amino-ethyl)-1-benzhydryl-5-chloro-1H-indol-3-yl]-propyl}-benzoic acid.
  • 1H NMR (300 MHz, DMSO-d6): δ=1.83 (br.m, 2H), 2.63 (br.m, 4H), 2.72 (br.m, 2H), 2.93 (br.m, 2H), 6.50 (d, 1H), 6.75 (d, 1H), 7.08 (m, 5H), 7.10 (br.s, 1H), 7.33 (m, 5H), 7.46 (br.s, 1H), 7.75 (d, 2H) ppm.
  • Many variations of the present invention not illustrated herein will occur to those skilled in the art. The present invention is not limited to the embodiments illustrated and described herein, but encompasses all the subject matter within the scope of the appended claims.

Claims (9)

1-12. (canceled)
13. A process for making the compound
Figure US20080177085A1-20080724-C00018
comprising the reaction step
Figure US20080177085A1-20080724-C00019
wherein Ar represents phenyl optionally substituted with one to three halogen atoms;
R represents C1-C6-alkyl, phenyl, —CH2O-phenyl, —CH2O-(C1-C6-alkyl), —CH2-phenyl, —CH2CH2-phenyl, or —CH2-phenyl—COOZ;
Z represents H or C1-C6-alkyl;
Ph represents phenyl; and
X represents a moiety selected from the group consisting of H, F, Cl, Br, C1-C10-alkyl, C3-C10-cycloalkyl, and C6-C10-aryl, the alkyl moiety being optionally substituted with one or more atoms selected from F, Cl and Br, and the cycloalkyl and aryl moieties being optionally substituted with from one to three substituents selected from F, Cl, Br and C1-C6-alkyl.
14. The process of claim 13 wherein X is F, Cl or Br; R is —CH2-phenyl, —CH2CH2-phenyl, or —CH2-phenyl—COOZ; and Z is H or C1-C6-alkyl.
15. The process of claim 14 wherein X is Cl, R is —CH2-phenyl—COOH, and Ar is 3,4-dichlorophenyl.
16. A process for making the compound
Figure US20080177085A1-20080724-C00020
comprising the step of reacting the compound
Figure US20080177085A1-20080724-C00021
in N,N-dimethylformamide in the presence of copper iodide to form the substituted indole compound
Figure US20080177085A1-20080724-C00022
wherein Ar represents phenyl optionally substituted with one to three halogen atoms;
R represents C1-C6-alkyl, phenyl, —CH2O-phenyl, —CH2O-(C1-C6-alkyl), —CH2-phenyl, —CH2CH2-phenyl, or —CH2-phenyl—COOZ;
Z represents H or C1-C6-alkyl;
Ph represents phenyl; and
X represents a moiety selected from the group consisting of H, F, Cl, Br, C1-C10-alkyl, C3-C10-cycloalkyl, and C6-C10-aryl, the alkyl moiety being optionally substituted with one or more atoms selected from F, Cl and Br, and the cycloalkyl and aryl moieties being optionally substituted with from one to three substituents selected from F, Cl, Br and C1-C6-alkyl.
17. The process of claim 16 wherein X is F, Cl or Br; R is —CH2-phenyl, —CH2CH2-phenyl, or —CH2-phenyl—COOZ; and Z is H or C1-C6-alkyl.
18. The process of claim 17 wherein X is Cl, R is —CH2-phenyl—COOH, and Ar is 3,4-dichlorophenyl.
19. A process for making the compound
Figure US20080177085A1-20080724-C00023
comprising the reaction steps
Figure US20080177085A1-20080724-C00024
20-22. (canceled)
US12/041,988 2003-09-30 2008-03-04 Process for the Synthesis of a CPLA2 Inhibitor Abandoned US20080177085A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/041,988 US20080177085A1 (en) 2003-09-30 2008-03-04 Process for the Synthesis of a CPLA2 Inhibitor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50723503P 2003-09-30 2003-09-30
US10/948,004 US7342119B2 (en) 2003-09-30 2004-09-23 Process for the synthesis of a CPLA2 inhibitor
US12/041,988 US20080177085A1 (en) 2003-09-30 2008-03-04 Process for the Synthesis of a CPLA2 Inhibitor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/948,004 Division US7342119B2 (en) 2003-09-30 2004-09-23 Process for the synthesis of a CPLA2 inhibitor

Publications (1)

Publication Number Publication Date
US20080177085A1 true US20080177085A1 (en) 2008-07-24

Family

ID=34381319

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/948,004 Expired - Fee Related US7342119B2 (en) 2003-09-30 2004-09-23 Process for the synthesis of a CPLA2 inhibitor
US12/041,988 Abandoned US20080177085A1 (en) 2003-09-30 2008-03-04 Process for the Synthesis of a CPLA2 Inhibitor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/948,004 Expired - Fee Related US7342119B2 (en) 2003-09-30 2004-09-23 Process for the synthesis of a CPLA2 inhibitor

Country Status (1)

Country Link
US (2) US7342119B2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605156B2 (en) * 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US7713964B2 (en) * 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
TW200510305A (en) 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
HN2004000536A (en) 2003-12-16 2009-02-18 Wyeth Corp A SYNTHESIS PROCEDURE FOR THE REDUCTIVE RENTAL OF THE POSITION C-3 OF INDOLES
AR053410A1 (en) * 2004-08-19 2007-05-09 Wyeth Corp PROCESS FOR SYNTHESIS OF INDOLES N-RENTED C-2, C-3 SUBSTITUTED. INTERMEDIARY COMPOUNDS
TW200718687A (en) * 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2
WO2007056279A2 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors
JP2010508302A (en) * 2006-10-31 2010-03-18 ワイス エルエルシー Solution of phospholipase enzyme inhibitor
EP2068829A2 (en) * 2006-10-31 2009-06-17 Wyeth Semi-solid formulations of phospholipase enzyme inhibitors

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144282A1 (en) * 2001-12-03 2003-07-31 Wyeth Inhibitors of cytosolic phospholipase A2
US20030149029A1 (en) * 2001-12-03 2003-08-07 Wyeth Methods for treating asthmatic conditions
US20030158405A1 (en) * 2001-12-03 2003-08-21 Wyeth N-benzhydryl indole compounds
US20030166649A1 (en) * 2001-12-03 2003-09-04 Wyeth Methods for treating arthritic disorders
US20040082785A1 (en) * 2001-12-03 2004-04-29 Wyeth Process for making an aldehyde
US20050020858A1 (en) * 2003-07-25 2005-01-27 Wyeth Advanced route for the synthesis of cPLA2 inhibitors
US20050049296A1 (en) * 2003-09-03 2005-03-03 Wyeth Process for the synthesis of cPLA2 inhibitors
US20050148770A1 (en) * 2003-12-16 2005-07-07 Wyeth Synthetic methodology for the reductive alkylation at the C-3 position of indoles
US20060014759A1 (en) * 2001-12-03 2006-01-19 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US20060041005A1 (en) * 2004-08-19 2006-02-23 Wyeth Process for the synthesis C-2, C-3 substituted N-alkylated indoles useful as CPLA2 inhibitors

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984735B2 (en) * 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
US20030144282A1 (en) * 2001-12-03 2003-07-31 Wyeth Inhibitors of cytosolic phospholipase A2
US20030158405A1 (en) * 2001-12-03 2003-08-21 Wyeth N-benzhydryl indole compounds
US20030166649A1 (en) * 2001-12-03 2003-09-04 Wyeth Methods for treating arthritic disorders
US20040082785A1 (en) * 2001-12-03 2004-04-29 Wyeth Process for making an aldehyde
US20030149029A1 (en) * 2001-12-03 2003-08-07 Wyeth Methods for treating asthmatic conditions
US6797708B2 (en) * 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
US6635771B2 (en) * 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
US20060014759A1 (en) * 2001-12-03 2006-01-19 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US20050020858A1 (en) * 2003-07-25 2005-01-27 Wyeth Advanced route for the synthesis of cPLA2 inhibitors
US6891065B2 (en) * 2003-07-25 2005-05-10 Wyeth Advanced route for the synthesis of cPLA2 inhibitors
US20050159613A1 (en) * 2003-07-25 2005-07-21 Wyeth Advanced route for the synthesis of cPLA2 inhibitors
US20050049296A1 (en) * 2003-09-03 2005-03-03 Wyeth Process for the synthesis of cPLA2 inhibitors
US20050148770A1 (en) * 2003-12-16 2005-07-07 Wyeth Synthetic methodology for the reductive alkylation at the C-3 position of indoles
US20060041005A1 (en) * 2004-08-19 2006-02-23 Wyeth Process for the synthesis C-2, C-3 substituted N-alkylated indoles useful as CPLA2 inhibitors
US7582772B2 (en) * 2004-08-19 2009-09-01 Wyeth Process for the synthesis C-2, C-3 substituted N-alkylated indoles useful as CPLA2 inhibitors

Also Published As

Publication number Publication date
US7342119B2 (en) 2008-03-11
US20050070723A1 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
US20080177085A1 (en) Process for the Synthesis of a CPLA2 Inhibitor
US20050159613A1 (en) Advanced route for the synthesis of cPLA2 inhibitors
US7781598B2 (en) Process for the preparation of substituted indoles
CA1216849A (en) Quinolone acids, processes for their preparation and antibacterial agents containing these compounds
JPH0776201B2 (en) Acid amide- and -imide derivatives of biscation and method for producing the same
FI93835C (en) Process for the preparation of 3- (benzothiazol-2-ylmethyl) -4-oxo-3-H-phthalazin-1-ylacetic acid derivative
US7667071B2 (en) Process for the preparation of gabapentin hydrochloride
US7582771B2 (en) Process for the synthesis of cPLA2 inhibitors
JP4223280B2 (en) Method for synthesizing 2-amino-5,8-dimethoxy [1,2,4] triazolo [1,5-c] pyrimidine
JP3378315B2 (en) Carbazolone derivative and method for preparing the same
US20060264491A1 (en) Telmisartan production process
US5986106A (en) Process for preparing 4-substituted-1H-indole-3-glyoxamides
SU1736334A3 (en) Method of alkylanilinofumarate synthesis
US20120065397A1 (en) Preparation of ketone amides
US4338452A (en) 1-and 2-(1-Alkyl-1H-tetrazol-5-yl-methyl)-1H-tetrazol-5-thiols and 1-cyanomethyl tetrazole-5-thiol
EP0662961B1 (en) Process of synthesizing useful intermediates of substituted imidazole compounds
WO2001081306A2 (en) Azide cyclization-based synthesis and intermediates for spla2 inhibitors
PL190872B1 (en) Method of obtaining heteroarylocarboxylic amides and esters and novel compounds
US8242276B2 (en) Methods for the preparation of N-(S)-1-azabicyclo[2.2.2]oct-3-yl-1H-indazole-3-carboxamide hydrochloride salt
US6812347B2 (en) Processes for the preparation of pesticidal compounds and novel intermediates thereof
US20070149606A1 (en) Process for producing phenylacetic acid derivative
US4847405A (en) Method for the preparation of anilinofumarate [quinoline-2,3- dicarboxylic]
KR0177152B1 (en) Phenylene diamines and a process for their preparation
US20120190849A1 (en) Processes for the preparation of vardenafil
JP4663105B2 (en) Method for producing 2-sulfonyl-4-oxypyridine derivative

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE